For the Inventor, By the Inventor

Enter assignee name

Biochem Pharma Inc.

Calculating rank

USPTO Granted Patents = 62

% Expired Patents = 8.1

Forward Citations = 1,208

Loading Chart...

Loading Chart...

85 inventors (with patents filed for the assignee):

Nghe Nguyen-Ba (18 out of 28 patents)

Tarek S Mansour (15 out of 17 patents)

Boulos Zacharie (10 out of 29 patents)

4. Haolun Jin (10 out of 12 patents)

5. Allan H Tse (9 out of 10 patents)

6. Bernard Belleau, Deceased (7 out of 8 patents)

7. Giorgio Attardo (6 out of 19 patents)

8. Gervais Dionne (6 out of 16 patents)

9. Rabindra Rej (5 out of 9 patents)

10. Dilip M Dixit (5 out of 9 patents)

11. M Arshad Siddiqui (5 out of 6 patents)

12. Yves St-Denis (5 out of 5 patents)

13. Bernard R Belleau (5 out of 16 patents)

14. Serge Lamothe (4 out of 6 patents)

15. Guy Falardeau (4 out of 10 patents)

Core Competencies:

Nucleoside Analogues

Antiviral Compounds

Flavivirus Infections

Leukemia Treatment

Immunomodulating Activity

Stereoselective Synthesis

Thrombin Inhibitors

1,3-Oxathiolanes

Dioxolane Nucleosides

Bicyclic Compounds

Polycyclic Alcaloid-Derivatives

Peptides

62 patents: Sort by Forward Citations

1. 6903224 - Substituted 1,3-oxathiolanes (2005-06-07),

2. 6784161 - Method for the treatment or prevention of flavivirus infections using nucleoside analogues (2004-08-31),

3. 6747036 - Methods of treating leukemia (2004-06-08),

4. 6743910 - Stereoselective synthesis of nucleoside analogues (2004-06-01),

5. 6630488 - Quinolizinones as integrin inhibitors (2003-10-07),

6. 6630480 - Methods of treating leukemia (2003-10-07),

7. 6605614 - [1,8] naphthyridine derivatives having antiviral activity (2003-08-12),

8. 6583149 - Method for the treatment or prevention of viral infection using nucleoside analogues (2003-06-24),

9. 6566365 - Method for the treatment of Flaviviridea viral infection using nucleoside analogues (2003-05-20),

10. 6545001 - Antiviral nucleoside analogues (2003-04-08),

11. 6541625 - Stereoselective synthesis of nucleoside analogues (2003-04-01),

12. 6534520 - Antiviral compounds (2003-03-18),

13. 6511983 - Pharmaceutical combination of antiviral agents (2003-01-28),

14. 6444656 - Antiviral phosphonate nucleotides (2002-09-03),

15. 6369066 - Substituted 1,3-oxathiolanes with antiviral properties (2002-04-09),

Company Overview

Biochem Pharma Inc., based in Laval, Canada, specializes in the development of nucleoside analogues and antiviral compounds. The company focuses on innovative treatments for flavivirus infections and leukemia, leveraging advanced techniques in stereoselective synthesis. Their research extends to immunomodulating activities and thrombin inhibitors, positioning them at the forefront of pharmaceutical advancements in these critical areas. Biochem Pharma is dedicated to addressing unmet medical needs through cutting-edge scientific exploration.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

62 Patents

#1 in Laval

#217 in Canada

#11,782 in the World

Biochem Pharma Inc.

Forward Citations = 1,208

85 inventors:

Nghe Nguyen-Ba (18 out of 28 patents)

Tarek S Mansour (15 out of 17 patents)

Boulos Zacharie (10 out of 29 patents)

4. Haolun Jin (10 out of 12 patents)

5. Allan H Tse (9 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biochem Pharma Inc.. Retrieved from https://idiyas.com/company/biochem-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…